clarithromycin has been researched along with thalidomide in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 18 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gidoh, M; Saito, H | 1 |
| Coleman, M; Leonard, J; Lyons, L; Michaeli, J; Nahum, K; Niesvizky, R; Pearse, R; Pekle, K | 1 |
| Anagnostopoulos, N; Dimopoulos, MA; Economopoulos, T; Hamilos, G; Margaritis, D; Matsouka, C; Panayiotidis, P; Tsatalas, C; Zomas, A | 1 |
| Coleman, M; Leonard, J; Lyons, L; Niesvizky, R; Szelenyi, H | 1 |
| Aboulafia, DM | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Chen-Kiang, S; Cho, HJ; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Harpel, J; Jalbrzikowski, J; Jayabalan, DS; Larow, A; Lent, R; Leonard, JP; Mark, T; Mathew, S; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Pekle, K; Schuster, MW; Shore, T; Tepler, J; Zafar, F | 1 |
| Christos, PJ; Coleman, M; Furst, JR; Harpel, J; Jayabalan, D; LaRow, A; Leonard, JP; Mark, T; Niesvizky, R; Pearse, RN; Schuster, MW; Shore, T; Stern, J; Zafar, F | 1 |
| Boyd, K; Clarke, P; Drake, M; Hull, DR; Jones, FC; Kettle, PJ; Morris, TC; Morrison, A; O'Reilly, P; Quinn, J | 1 |
| Agrawal, YP; Cesarman, E; Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furman, RR; Jayabalan, D; Lee, JW; Lent, R; Leonard, JP; Mark, T; Matthew, S; Mazumdar, M; Niesvizky, R; Pearse, RN; Wang, YL | 1 |
| Chen-Kiang, S; Coleman, M; Dispenzieri, A; Fonseca, R; Gay, F; Gertz, MA; Greipp, PR; Jayabalan, DS; Kumar, S; Kyle, RA; Lacy, MQ; Leonard, J; Lust, JA; Mark, T; Niesvizky, R; Pearse, R; Rajkumar, SV; Roy, V; Stewart, AK; Witzig, TE | 1 |
| Chen-Kiang, S; Christos, P; Coleman, M; Jayabalan, D; Mark, T; Niesvizky, R; Pearse, R; Pekle, K; Rossi, A; Zafar, F | 1 |
| Fujiwara, T; Fukuhara, N; Harigae, H; Ishizawa, K; Kato, H; Katsuoka, Y; Okitsu, Y; Onishi, Y; Takagawa, M | 1 |
| Bowman, IA; Chen-Kiang, S; Coleman, M; Ely, S; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, K; Quinn, R; Rodriguez, M; Rossi, AC; Shah, M; Zafar, F | 1 |
| Borrello, I; Ghosh, N; Huff, CA; Tucker, N; Wozney, J; Zahurak, M | 1 |
| Borrello, I; Bui, M; Ghosh, N; Noonan, KA; Rudraraju, L | 1 |
| Abe, T; Fujii, S; Jomen, W; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Sakurai, T; Sato, M; Usami, M; Yamada, M; Yoshida, M | 1 |
| Qiu, XH; Zhai, YP | 1 |
| Akasaka, H; Ito, K; Kodaka, T; Sakane, E; Takahashi, T; Tsunemine, H; Yoshioka, S | 1 |
| Cao, HQ; Li, HQ; Mei, JG; Qiu, XH; Shao, JJ | 1 |
| Coleman, M; Mark, TM | 1 |
| Becker, PS; Bensinger, W; Holmberg, LA | 1 |
| Abe, T; Ameda, S; Fujii, S; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Miura, S; Sakano, H; Sato, K; Shibata, T; Uemura, N; Yamada, M | 1 |
| Abumiya, M; Kanno, S; Kobayashi, T; Miura, M; Niioka, T; Takahashi, N | 1 |
| Hoshino, K; Imai, G; Kojima, M; Ooi, A; Takemori, N | 1 |
| Boyer, A; Coleman, M; Forsberg, PA; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, KA; Perry, A; Rossi, AC; Tegnestam, L | 1 |
7 review(s) available for clarithromycin and thalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Present status of studies on antileprosy drugs].
Topics: Animals; Clarithromycin; Dapsone; Drug Therapy, Combination; Humans; Immunologic Factors; Leprostatic Agents; Minocycline; Prothionamide; Quinolones; Rifampin; Rifamycins; Thalidomide | 1995 |
Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Thalidomide; Waldenstrom Macroglobulinemia | 2003 |
Thalidomide-based treatment for HIV-associated multiple myeloma: a case report.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Bone Marrow Examination; CD4 Lymphocyte Count; Clarithromycin; Dexamethasone; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome; Viral Load; Viral Matrix Proteins | 2003 |
[Progress of research on clarithromycin for treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Multiple Myeloma; Thalidomide | 2015 |
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisolone; Recurrence; Thalidomide | 2015 |
[Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2017 |
7 trial(s) available for clarithromycin and thalidomide
| Article | Year |
|---|---|
Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Follow-Up Studies; Humans; Middle Aged; Omeprazole; Thalidomide; Treatment Outcome; Waldenstrom Macroglobulinemia | 2003 |
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Time Factors | 2008 |
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Stem Cells; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2008 |
Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Quality of Life; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Clarithromycin; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide; Thrombocytopenia | 2010 |
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Analysis; Thalidomide; Treatment Outcome | 2019 |
16 other study(ies) available for clarithromycin and thalidomide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Disease Progression; Female; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Thalidomide; Time Factors; Treatment Outcome; Waldenstrom Macroglobulinemia | 2002 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Clarithromycin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoglobulins; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Thalidomide | 2008 |
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoadjuvant Therapy; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2013 |
Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.
Topics: Clarithromycin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2013 |
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Clarithromycin; Dexamethasone; Humans; Immune Tolerance; Immunologic Factors; Interleukin-4 Receptor alpha Subunit; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Phosphodiesterase 5 Inhibitors; T-Lymphocytes; Tadalafil; Thalidomide | 2014 |
[Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Immunoglobulin A; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells.
Topics: Clarithromycin; Drug Synergism; Humans; Immunosuppressive Agents; Multiple Myeloma; Signal Transduction; Thalidomide | 2016 |
It's Time to Take Clarithromycin Seriously in Multiple Myeloma.
Topics: Clarithromycin; Humans; Immunosuppressive Agents; Multiple Myeloma; Thalidomide | 2016 |
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Consolidation Chemotherapy; Dexamethasone; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Clarithromycin; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2018 |
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clarithromycin; Diabetes Mellitus; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2018 |